A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

President Trump has vowed to impose tariffs on China, Mexico, and Canada. They could make common medicines less affordable.

On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

AstraZeneca's bold vision for a cutting-edge vaccine facility in Speke is caught in a web of delays, leaving the biotech ...

AstraZeneca PLC ADR closed 22.49% short of its 52-week high of $87.68, which the company reached on August 30th.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

AstraZeneca PLC AZN shares rallied 2.39% to £110.52 Tuesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.33% to 8,548.29.

The addition of anthracyclines to adjuvant taxane-based chemotherapy improved survival for certain high-risk patients with ...